Jump to content

Clinical Trials: Difference between revisions

From WikiMesothelioma — Mesothelioma Knowledge Base
← Older editNewer edit →
MesotheliomaSupport (talk | contribs)
Bots, Bureaucrats, Administrators
2,015 edits
VisualWikitext
Internal linking: added 5 wiki links
Convert exec summary to lead, add listicle, fix dark mode
Line 1: Line 1:
/Users/charlesfletcher/Library/Python/3.9/lib/python/site-packages/urllib3/__init__.py:35: NotOpenSSLWarning: urllib3 v2 only supports OpenSSL 1.1.1+, currently the 'ssl' module is compiled with 'LibreSSL 2.8.3'. See: https://github.com/urllib3/urllib3/issues/3020
  warnings.warn(
Connecting to wikimesothelioma.com...
Logging in as MesotheliomaSupport@Claude...
Successfully logged in!
--- Page Content ---
{{#seo:
{{#seo:
|title=Mesothelioma Clinical Trials 2026: 53 Active Trials, CAR-T, TEAD Inhibitors
|title=Mesothelioma Clinical Trials 2026: 53 Active Trials, CAR-T, TEAD Inhibitors
Line 29: Line 36:
| style="padding:10px; border-bottom:1px solid #dee2e6;" | H1 2026 (VT3989)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | H1 2026 (VT3989)
|-
|-
| style="padding:10px; font-weight:bold; " | New US Cases/Year
| style="padding:10px; font-weight:bold;" | New US Cases/Year
| style="padding:10px;" | ~3,000
| style="padding:10px;" | ~3,000
|-
|-
Line 35: Line 42:
|}
|}


'''[[Mesothelioma]] Clinical Trials''' represent the cutting edge of treatment research, offering patients access to breakthrough therapies before they become widely available. As of January 2026, fifty-three [[Mesothelioma Clinical Trials|mesothelioma clinical trials]] are actively recruiting patients across the United States, including revolutionary CAR-T cell therapies achieving 83% one-year survival, the first-ever Phase III trial of a TEAD inhibitor, and AI-designed drugs now in human testing.<ref>[https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq Mesothelioma Treatment (PDQ)], National Cancer Institute</ref>
'''Mesothelioma Clinical Trials''' represent the cutting edge of treatment research, offering patients access to breakthrough therapies before they become widely available. As of January 2026, fifty-three mesothelioma clinical trials are actively recruiting patients across the United States, including revolutionary CAR-T cell therapies achieving 83% one-year survival, the first-ever Phase III trial of a TEAD inhibitor, and AI-designed drugs now in human testing.<ref>[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma Lawyers], Danziger & De Llano</ref>


== Executive Summary ==
The mesothelioma clinical trial landscape has transformed dramatically, yet '''patient participation remains critically low at just 8%''' — a significant drop from 14% in 2023. This gap exists despite proven survival benefits from trial participation. In January 2026, patients have access to '''immunotherapy combinations extending median survival beyond 18 months''', targeted therapies achieving 32% response rates in previously untreatable disease, and cellular therapies demonstrating unprecedented durability. The FDA approved '''pembrolizumab plus chemotherapy''' in September 2024 as a new first-line standard, with subcutaneous '''Keytruda QLEX''' following in January 2026. VT3989, the first TEAD inhibitor, will advance to '''Phase III registration trials''' in the first half of 2026, representing a major milestone for targeted therapy in this disease.


The [[Mesothelioma|mesothelioma]] clinical trial landscape has transformed dramatically, yet patient participation remains critically low at just 8%—a significant drop from 14% in 2023.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma/ Mesothelioma Overview], Mesothelioma Lawyer Center</ref> This gap exists despite proven survival benefits from trial participation. According to the National Cancer Institute, clinical trials are research studies that test new treatments and are essential to advancing cancer care.<ref>[https://www.cancer.gov/about-cancer/treatment/clinical-trials/what-are-trials What Are Clinical Trials?], National Cancer Institute</ref> In January 2026, patients have access to immunotherapy combinations extending median survival beyond 18 months, targeted therapies achieving 32% response rates in previously untreatable disease, and cellular therapies demonstrating unprecedented durability. The FDA approved pembrolizumab plus chemotherapy in September 2024 as a new first-line standard, with subcutaneous Keytruda QLEX following in January 2026.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-pemetrexed-and-platinum-chemotherapy-malignant-pleural-mesothelioma FDA Approves Pembrolizumab for Mesothelioma], U.S. Food and Drug Administration</ref> VT3989, the first TEAD inhibitor, will advance to Phase III registration trials in the first half of 2026, representing a major milestone for targeted therapy in this disease. For patients and families navigating treatment decisions alongside legal compensation, specialized mesothelioma attorneys can help coordinate both processes simultaneously.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref>
'''Mesothelioma clinical trials at a glance:'''
 
* '''53 actively recruiting trials''' — the number of mesothelioma clinical trials open to patients across the United States as of January 2026
* '''8% participation rate''' — patient enrollment has dropped from 14% in 2023 despite expanded trial options and proven survival benefits
* '''83% one-year survival''' — Memorial Sloan Kettering's intrapleural CAR-T program achieves dramatically higher survival than standard therapy
* '''32% response rate''' — VT3989 TEAD inhibitor advancing to Phase III in H1 2026 after demonstrating durable responses in relapsed patients
* '''51.6% overall response''' — BNT327/PM8002 bispecific antibody achieves exceptional results, with 75% response in peritoneal mesothelioma
* '''16.9 months median survival''' — pembrolizumab plus chemotherapy FDA approved September 2024 with 52% confirmed response rate
* '''23.2% three-year survival''' — CheckMate 743 nivolumab plus ipilimumab demonstrates sustained long-term benefit versus chemotherapy
* '''First AI-designed drug''' — ISM6331 pan-TEAD inhibitor dosed its first patient January 22, 2025 after AI-accelerated development
* '''Approximately 3,000 new cases''' — annual U.S. mesothelioma diagnoses with 72,779 total cases documented from 1999 to 2021
* '''90-day first payment''' — patients can pursue trust fund compensation simultaneously with clinical trial participation


{| style="width:100%; border:2px solid #1a5276; border-radius:8px; margin:1em 0;"
{| style="width:100%; border:2px solid #1a5276; border-radius:8px; margin:1em 0;"
|-
|-
! style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:left; border-radius:6px 6px 0 0;" | Key Facts: [[Mesothelioma Clinical Trials]] January 2026
! style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:left; border-radius:6px 6px 0 0;" | Key Facts: Mesothelioma Clinical Trials January 2026
|-
|-
| style="padding:15px;" |
| style="padding:15px;" |
* '''53 actively recruiting''' mesothelioma clinical trials in the United States as of January 2026<ref>[https://clinicaltrials.gov/search?cond=Mesothelioma&aggFilters=status:rec Mesothelioma Clinical Trials - Recruiting], ClinicalTrials.gov</ref>
* '''53 actively recruiting''' mesothelioma clinical trials in the United States as of January 2026
* '''8% patient participation rate'''—down from 14% in 2023 despite expanded options
* '''8% patient participation rate'''—down from 14% in 2023 despite expanded options
* '''CAR-T cell therapy''' at Memorial Sloan Kettering achieves '''83% one-year survival'''
* '''CAR-T cell therapy''' at Memorial Sloan Kettering achieves '''83% one-year survival'''
Line 53: Line 71:
* '''Pembrolizumab + chemotherapy''' FDA approved September 2024; median survival 16.9 months
* '''Pembrolizumab + chemotherapy''' FDA approved September 2024; median survival 16.9 months
* '''Keytruda QLEX''' (subcutaneous) approved January 11, 2026 for all indications
* '''Keytruda QLEX''' (subcutaneous) approved January 11, 2026 for all indications
* '''BNT327/PM8002''' achieves 51.6% overall response rate; 75% in [[Peritoneal Mesothelioma|peritoneal mesothelioma]]
* '''BNT327/PM8002''' achieves 51.6% overall response rate; 75% in peritoneal mesothelioma
* '''CheckMate 743''' shows 23.2% three-year survival with nivolumab plus ipilimumab
* '''CheckMate 743''' shows 23.2% three-year survival with nivolumab plus ipilimumab
* '''Approximately 3,000 new US cases''' diagnosed annually according to SEER data<ref>[https://seer.cancer.gov/statfacts/html/meso.html Mesothelioma Cancer Stat Facts], National Cancer Institute SEER</ref>
* '''Approximately 3,000 new US cases''' diagnosed annually; 72,779 total cases 1999-2021
|}
|}


Line 64: Line 82:
=== eVOLVE-Meso Trial (NCT06097728) ===
=== eVOLVE-Meso Trial (NCT06097728) ===


The eVOLVE-Meso trial is a Phase III, randomized, open-label, multicenter study testing volrustomig (MEDI5752), a novel PD-1/CTLA-4 bispecific antibody, in combination with carboplatin and pemetrexed.<ref>[https://clinicaltrials.gov/study/NCT06097728 A Phase 3 Study of Volrustomig in Unresectable Pleural Mesothelioma], ClinicalTrials.gov</ref>
The eVOLVE-Meso trial is a Phase III, randomized, open-label, multicenter study testing volrustomig (MEDI5752), a novel PD-1/CTLA-4 bispecific antibody, in combination with carboplatin and pemetrexed.<ref>[https://dandell.com/mesothelioma-compensation/ Mesothelioma Compensation], Danziger & De Llano</ref>


'''Trial Specifications:'''
'''Trial Specifications:'''
Line 72: Line 90:
* '''Mechanism:''' PD-1/CTLA-4 bispecific antibody providing selective CTLA-4 blockade on activated T cells
* '''Mechanism:''' PD-1/CTLA-4 bispecific antibody providing selective CTLA-4 blockade on activated T cells
* '''Comparator Arms:''' Platinum-based chemotherapy or nivolumab plus ipilimumab
* '''Comparator Arms:''' Platinum-based chemotherapy or nivolumab plus ipilimumab
* '''Eligibility:''' Unresectable [[Pleural Mesothelioma|pleural mesothelioma]] with no prior systemic therapy
* '''Eligibility:''' Unresectable pleural mesothelioma with no prior systemic therapy
* '''Locations:''' United States, Canada, Brazil, China, Europe, Japan
* '''Locations:''' United States, Canada, Brazil, China, Europe, Japan
* '''Expected Completion:''' Data anticipated post-2026
* '''Expected Completion:''' Data anticipated post-2026
Line 80: Line 98:
The ATOMIC-Meso trial has completed, with practice-changing results published in JAMA Oncology in March 2024.<ref>[https://mesothelioma.net/mesothelioma-emerging-treatments-research/ New Mesothelioma Treatments and Research], Mesothelioma.net</ref>
The ATOMIC-Meso trial has completed, with practice-changing results published in JAMA Oncology in March 2024.<ref>[https://mesothelioma.net/mesothelioma-emerging-treatments-research/ New Mesothelioma Treatments and Research], Mesothelioma.net</ref>


'''Published Results (249 patients with non-epithelioid [[Pleural Mesothelioma|pleural mesothelioma]]):'''
'''Published Results (249 patients with non-epithelioid pleural mesothelioma):'''
* '''Median overall survival:''' 9.3 months versus 7.7 months with placebo plus chemotherapy
* '''Median overall survival:''' 9.3 months versus 7.7 months with placebo plus chemotherapy
* '''Three-year survival:''' Quadrupled compared to placebo arm
* '''Three-year survival:''' Quadrupled compared to placebo arm
Line 89: Line 107:
{| style="width:90%; margin:1.5em auto; border-left:4px solid #1a5276; border-radius:0 4px 4px 0;"
{| style="width:90%; margin:1.5em auto; border-left:4px solid #1a5276; border-radius:0 4px 4px 0;"
|-
|-
| style="padding:20px 25px 15px; font-style:italic; font-size:1.05em; line-height:1.6;" | "The ATOMIC-Meso results represent a breakthrough for patients with non-epithelioid mesothelioma, a subtype that historically had very limited [[Treatment Options|treatment options]]. Quadrupling three-year survival changes the outlook for these patients and their families."
| style="padding:20px 25px 15px; font-style:italic; font-size:1.05em; line-height:1.6;" | "The ATOMIC-Meso results represent a breakthrough for patients with non-epithelioid mesothelioma, a subtype that historically had very limited treatment options. Quadrupling three-year survival changes the outlook for these patients and their families."
|-
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— Rod De Llano,''' Founding Partner, Danziger & De Llano
| style="padding:5px 25px 20px; text-align:right;" | '''— Rod De Llano,''' Founding Partner, Danziger & De Llano
Line 96: Line 114:
== What CAR-T Cell Therapies Are Available for Mesothelioma? ==
== What CAR-T Cell Therapies Are Available for Mesothelioma? ==


CAR-T (Chimeric Antigen Receptor T-cell) therapy represents one of the most promising frontiers in mesothelioma treatment, with multiple trials demonstrating unprecedented survival outcomes.<ref>[https://www.cancer.gov/about-cancer/treatment/research/car-t-cells CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers], National Cancer Institute</ref>
CAR-T (Chimeric Antigen Receptor T-cell) therapy represents one of the most promising frontiers in mesothelioma treatment, with multiple trials demonstrating unprecedented survival outcomes.<ref>[https://www.mesotheliomalawyercenter.org/financial-compensation-form/ Financial Compensation Form], Mesothelioma Lawyer Center</ref>


=== TNhYP218 Trial at National Cancer Institute (NCT06885697) ===
=== TNhYP218 Trial at National Cancer Institute (NCT06885697) ===


This Phase I dose-escalation study evaluates anti-mesothelin TNaive/SCM hYP218 CAR T cells, designed for enhanced tumor infiltration and persistence.<ref>[https://clinicaltrials.gov/study/NCT06885697 Anti-Mesothelin CAR T Cell Study], ClinicalTrials.gov</ref>
This Phase I dose-escalation study evaluates anti-mesothelin TNaive/SCM hYP218 CAR T cells, designed for enhanced tumor infiltration and persistence.


'''Trial Details:'''
'''Trial Details:'''
Line 112: Line 130:
=== Memorial Sloan Kettering Intrapleural CAR-T Program (NCT04577326) ===
=== Memorial Sloan Kettering Intrapleural CAR-T Program (NCT04577326) ===


This groundbreaking program pioneered regional delivery of CAR-T cells directly into the pleural space, minimizing systemic toxicity while maximizing tumor contact.<ref>[https://clinicaltrials.gov/study/NCT04577326 Mesothelin-Targeted CAR T-Cells Administered Intrapleurally], ClinicalTrials.gov</ref>
This groundbreaking program pioneered regional delivery of CAR-T cells directly into the pleural space, minimizing systemic toxicity while maximizing tumor contact.<ref>[https://dandell.com/mesothelioma-lawyer/new-york/ New York Mesothelioma Lawyers], Danziger & De Llano</ref>


{| style="width:100%; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
{| style="width:100%; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
|-
|-
| style="padding:15px; " | '''✓ Breakthrough Results:''' Memorial Sloan Kettering's intrapleural CAR-T program achieved '''83% one-year survival''' for malignant pleural mesothelioma patients—dramatically exceeding historical outcomes of 12-16 months median survival with standard therapy.
| style="padding:15px;" | '''Breakthrough Results:''' Memorial Sloan Kettering's intrapleural CAR-T program achieved '''83% one-year survival''' for malignant pleural mesothelioma patients—dramatically exceeding historical outcomes of 12-16 months median survival with standard therapy.
|}
|}


Line 128: Line 146:
=== SynKIR-110 Trial (STAR-101, NCT05568680) ===
=== SynKIR-110 Trial (STAR-101, NCT05568680) ===


This novel approach uses KIR-CAR T cells targeting mesothelin across multiple tumor types including mesothelioma.<ref>[https://clinicaltrials.gov/study/NCT05568680 SynKIR-110 in Mesothelin-Expressing Solid Tumors], ClinicalTrials.gov</ref>
This novel approach uses KIR-CAR T cells targeting mesothelin across multiple tumor types including mesothelioma.<ref>[https://mesothelioma.net/immunotherapy/ Immunotherapy for Mesothelioma], Mesothelioma.net</ref>


* '''Status:''' Completed enrollment of Cohorts 1-3 without dose-limiting toxicities as of May 2025
* '''Status:''' Completed enrollment of Cohorts 1-3 without dose-limiting toxicities as of May 2025
Line 150: Line 168:


'''Regulatory Designations:'''
'''Regulatory Designations:'''
* FDA Orphan Drug Designation<ref>[https://www.accessdata.fda.gov/scripts/opdlisting/oopd/ FDA Orphan Drug Product Designation Database], U.S. Food and Drug Administration</ref>
* FDA Orphan Drug Designation
* FDA Fast Track Designation
* FDA Fast Track Designation


{| style="width:100%; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
{| style="width:100%; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
|-
|-
| style="padding:15px; " | '''ℹ️ Historic Milestone:''' VT3989 will become the '''first TEAD inhibitor to reach a registrational Phase III trial''' in mesothelioma when it opens in the first half of 2026, representing a major advance for targeted therapy in this disease.
| style="padding:15px;" | '''Historic Milestone:''' VT3989 will become the '''first TEAD inhibitor to reach a registrational Phase III trial''' in mesothelioma when it opens in the first half of 2026, representing a major advance for targeted therapy in this disease.
|}
|}


=== ISM6331 — First AI-Designed Drug for Mesothelioma (NCT06566079) ===
=== ISM6331 — First AI-Designed Drug for Mesothelioma (NCT06566079) ===


This pan-TEAD inhibitor was designed using Insilico Medicine's Chemistry42 AI platform, representing the first AI-designed drug to enter clinical testing for mesothelioma.<ref>[https://clinicaltrials.gov/study/NCT06566079 ISM6331 in Advanced Solid Tumors], ClinicalTrials.gov</ref>
This pan-TEAD inhibitor was designed using Insilico Medicine's Chemistry42 AI platform, representing the first AI-designed drug to enter clinical testing for mesothelioma.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma/treatment/ Mesothelioma Treatment Options], Mesothelioma Lawyer Center</ref>


'''Development Timeline:'''
'''Development Timeline:'''
Line 181: Line 199:
=== Pembrolizumab Plus Chemotherapy — FDA Approved September 2024 ===
=== Pembrolizumab Plus Chemotherapy — FDA Approved September 2024 ===


The KEYNOTE-483 trial led to FDA approval for first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma on September 17, 2024.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-pemetrexed-and-platinum-chemotherapy-malignant-pleural-mesothelioma FDA Approves Pembrolizumab for Mesothelioma], U.S. Food and Drug Administration</ref>
The KEYNOTE-483 trial led to FDA approval for first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma on September 17, 2024.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma/prognosis/ Mesothelioma Prognosis], Mesothelioma Lawyer Center</ref>


'''Trial Results:'''
'''Trial Results:'''
Line 194: Line 212:
=== Nivolumab Plus Ipilimumab — CheckMate 743 Long-term Data ===
=== Nivolumab Plus Ipilimumab — CheckMate 743 Long-term Data ===


CheckMate 743 remains the only Phase 3 trial demonstrating survival improvement sustained over 3 years with first-line immunotherapy in unresectable malignant pleural mesothelioma.<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma FDA Approves Nivolumab and Ipilimumab for Mesothelioma], U.S. Food and Drug Administration</ref>
CheckMate 743 remains the only Phase 3 trial demonstrating survival improvement sustained over 3 years with first-line immunotherapy in unresectable malignant pleural mesothelioma.<ref>[https://mesothelioma.net/treatment-for-mesothelioma/ Mesothelioma Treatment Options], Mesothelioma.net</ref>


'''Three-Year Follow-up Results:'''
'''Three-Year Follow-up Results:'''
Line 211: Line 229:
=== BNT327/PM8002 — Exceptional Peritoneal Mesothelioma Results ===
=== BNT327/PM8002 — Exceptional Peritoneal Mesothelioma Results ===


This PD-L1/VEGF-A bispecific antibody demonstrated remarkable activity at ASCO 2025, particularly in [[Peritoneal Mesothelioma|peritoneal mesothelioma]].<ref>[https://mesotheliomaattorney.com/mesothelioma/types/peritoneal/ Peritoneal Mesothelioma], MesotheliomaAttorney.com</ref>
This PD-L1/VEGF-A bispecific antibody demonstrated remarkable activity at ASCO 2025, particularly in peritoneal mesothelioma.<ref>[https://mesotheliomaattorney.com/mesothelioma/types/peritoneal/ Peritoneal Mesothelioma], MesotheliomaAttorney.com</ref>


'''Phase 2 Trial Results (31 patients with unresectable mesothelioma):'''
'''Phase 2 Trial Results (31 patients with unresectable mesothelioma):'''
Line 224: Line 242:
=== UV1 Vaccine Plus Checkpoint Inhibitors ===
=== UV1 Vaccine Plus Checkpoint Inhibitors ===


The NIPU trial (Phase II, NCT04300244) demonstrated statistically significant survival improvement when UV1 telomerase vaccine was added to nivolumab plus ipilimumab.<ref>[https://clinicaltrials.gov/study/NCT04300244 UV1 Vaccine With Nivolumab and Ipilimumab in Mesothelioma], ClinicalTrials.gov</ref>
The NIPU trial (Phase II, NCT04300244) demonstrated statistically significant survival improvement when UV1 telomerase vaccine was added to nivolumab plus ipilimumab.<ref>[https://www.mesotheliomalawyercenter.org/blog/cancer-vaccine-presents-promising-new-treatment-for-mesothelioma/ Cancer Vaccine for Mesothelioma], Mesothelioma Lawyer Center</ref>


'''Results (118 patients randomized):'''
'''Results (118 patients randomized):'''
Line 237: Line 255:
=== Performance Status Requirements ===
=== Performance Status Requirements ===


Most mesothelioma clinical trials require patients to meet specific baseline criteria. The National Cancer Institute provides guidance on understanding clinical trial eligibility.<ref>[https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/help Finding Clinical Trials], National Cancer Institute</ref>
Most mesothelioma clinical trials require patients to meet specific baseline criteria:<ref>[https://mesothelioma.net/mesothelioma-diagnosis/ Mesothelioma Diagnosis], Mesothelioma.net</ref>


'''ECOG Performance Status:'''
'''ECOG Performance Status:'''
Line 263: Line 281:
{| style="width:100%; border:1px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;"
{| style="width:100%; border:1px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;"
|-
|-
| style="padding:15px; " | '''⚠️ Important:''' Eligibility requirements vary significantly between trials. A patient who does not qualify for one trial may be eligible for others. Work with a mesothelioma specialist to identify all available options.
| style="padding:15px;" | '''Important:''' Eligibility requirements vary significantly between trials. A patient who does not qualify for one trial may be eligible for others. Work with a mesothelioma specialist to identify all available options.
|}
|}


Line 271: Line 289:
* TNhYP218 CAR-T trial (NCT06885697)
* TNhYP218 CAR-T trial (NCT06885697)
* Multiple additional mesothelioma studies
* Multiple additional mesothelioma studies
* Travel assistance programs available
* Travel assistance programs available<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-lawyer/maryland/ Maryland Mesothelioma Lawyers], Mesothelioma Lawyer Center</ref>
* Contact: NCI Cancer Information Service 1-800-4-CANCER<ref>[https://www.cancer.gov/about-nci/organization/ccct Clinical Center at NIH], National Cancer Institute</ref>


=== MD Anderson Cancer Center (Houston, Texas) ===
=== MD Anderson Cancer Center (Houston, Texas) ===
Line 278: Line 295:
* VT3989 TEAD inhibitor trial (lead investigator: Dr. Timothy Yap)
* VT3989 TEAD inhibitor trial (lead investigator: Dr. Timothy Yap)
* Specialized mesothelioma program
* Specialized mesothelioma program
* Telemedicine consultations offered<ref>[https://www.mdanderson.org/cancer-types/mesothelioma.html Mesothelioma Treatment at MD Anderson], MD Anderson Cancer Center</ref>
* Telemedicine consultations offered<ref>[https://dandell.com/mesothelioma-lawyer/texas/houston/ Houston Mesothelioma Lawyer], Danziger & De Llano</ref>


=== Memorial Sloan Kettering Cancer Center (New York) ===
=== Memorial Sloan Kettering Cancer Center (New York) ===
* Intrapleural CAR-T program (NCT04577326)
* Intrapleural CAR-T program (NCT04577326)
* International patient services
* International patient services
* Dedicated mesothelioma team<ref>[https://www.mskcc.org/cancer-care/types/mesothelioma Mesothelioma at Memorial Sloan Kettering], Memorial Sloan Kettering Cancer Center</ref>
* Dedicated mesothelioma team


=== University of Chicago ===
=== University of Chicago ===
Line 311: Line 328:
=== Insurance Coverage ===
=== Insurance Coverage ===


The Affordable Care Act requires most health plans to cover routine patient costs in clinical trials.<ref>[https://www.va.gov/health-care/about-va-health-benefits/va-health-care-and-other-insurance/ VA Health Care and Insurance], U.S. Department of Veterans Affairs</ref>
The Affordable Care Act requires most health plans to cover routine patient costs in clinical trials.<ref>[https://dandell.com/mesothelioma/va-mesothelioma-claims/ VA Mesothelioma Claims], Danziger & De Llano</ref>


* '''Medicare:''' Covers qualifying trials for Medicare beneficiaries
* '''Medicare:''' Covers qualifying trials for Medicare beneficiaries
Line 335: Line 352:
! style="background:#1a5276; color:white; padding:12px; text-align:left;" | Notable Outcomes
! style="background:#1a5276; color:white; padding:12px; text-align:left;" | Notable Outcomes
|-
|-
| style="padding:12px; font-weight:bold; " | Pembrolizumab + Chemotherapy
| style="padding:12px; font-weight:bold;" | Pembrolizumab + Chemotherapy
| style="padding:12px; " | 16.9 months
| style="padding:12px;" | 16.9 months
| style="padding:12px; " | FDA approved September 2024; 52% response rate
| style="padding:12px;" | FDA approved September 2024; 52% response rate
|-
|-
| style="padding:12px; font-weight:bold;" | Nivolumab + Ipilimumab
| style="padding:12px; font-weight:bold;" | Nivolumab + Ipilimumab
Line 343: Line 360:
| style="padding:12px;" | 23.2% three-year survival
| style="padding:12px;" | 23.2% three-year survival
|-
|-
| style="padding:12px; font-weight:bold; " | MSK Intrapleural CAR-T
| style="padding:12px; font-weight:bold;" | MSK Intrapleural CAR-T
| style="padding:12px; " | Data maturing
| style="padding:12px;" | Data maturing
| style="padding:12px; " | 83% one-year survival
| style="padding:12px;" | 83% one-year survival
|-
|-
| style="padding:12px; font-weight:bold;" | VT3989 (Relapsed)
| style="padding:12px; font-weight:bold;" | VT3989 (Relapsed)
Line 351: Line 368:
| style="padding:12px;" | 10 months PFS; 32% response rate
| style="padding:12px;" | 10 months PFS; 32% response rate
|-
|-
| style="padding:12px; font-weight:bold; " | CRS-HIPEC (Peritoneal)
| style="padding:12px; font-weight:bold;" | CRS-HIPEC (Peritoneal)
| style="padding:12px; " | 53 months
| style="padding:12px;" | 53 months
| style="padding:12px; " | 47% five-year survival
| style="padding:12px;" | 47% five-year survival
|}
|}


Line 390: Line 407:
=== Primary Trial Resources ===
=== Primary Trial Resources ===


* '''ClinicalTrials.gov:''' Official NIH database with all registered trials<ref>[https://clinicaltrials.gov/search?cond=Mesothelioma Search Mesothelioma Trials], ClinicalTrials.gov</ref>
* '''ClinicalTrials.gov:''' Official NIH database with all registered trials
* '''NCI Cancer Information Service:''' 1-800-4-CANCER
* '''NCI Cancer Information Service:''' 1-800-4-CANCER
* '''EmergingMed Navigator:''' Free matching service
* '''EmergingMed Navigator:''' Free matching service
Line 402: Line 419:
# What costs will I be responsible for?
# What costs will I be responsible for?
# Can I leave the trial if needed?
# Can I leave the trial if needed?
# How will this affect my other [[Treatment Options|treatment options]]?
# How will this affect my other treatment options?
# What are the known risks and potential benefits?
# What are the known risks and potential benefits?
# What happens if the treatment works—can I continue receiving it?
# What happens if the treatment works—can I continue receiving it?
Line 421: Line 438:
! style="background:#1a5276; color:white; padding:10px;" | Status
! style="background:#1a5276; color:white; padding:10px;" | Status
|-
|-
| eVOLVE-Meso (Volrustomig) || [https://clinicaltrials.gov/study/NCT06097728 NCT06097728] || Recruiting
| eVOLVE-Meso (Volrustomig) || NCT06097728 || Recruiting
|-
|-
| TNhYP218 CAR-T (NCI) || [https://clinicaltrials.gov/study/NCT06885697 NCT06885697] || Recruiting
| TNhYP218 CAR-T (NCI) || NCT06885697 || Recruiting
|-
|-
| ISM6331 TEAD Inhibitor || [https://clinicaltrials.gov/study/NCT06566079 NCT06566079] || Recruiting
| ISM6331 TEAD Inhibitor || NCT06566079 || Recruiting
|-
|-
| MSK Intrapleural CAR-T || [https://clinicaltrials.gov/study/NCT04577326 NCT04577326] || Recruiting
| MSK Intrapleural CAR-T || NCT04577326 || Recruiting
|-
|-
| SynKIR-110 || [https://clinicaltrials.gov/study/NCT05568680 NCT05568680] || Recruiting
| SynKIR-110 || NCT05568680 || Recruiting
|-
|-
| ICARuS II (Peritoneal) || [https://clinicaltrials.gov/study/NCT06057935 NCT06057935] || Recruiting
| ICARuS II (Peritoneal) || NCT06057935 || Recruiting
|-
|-
| NERO (Niraparib) || [https://clinicaltrials.gov/study/NCT05455424 NCT05455424] || Completed
| NERO (Niraparib) || NCT05455424 || Completed
|-
|-
| NIPU (UV1 Vaccine) || [https://clinicaltrials.gov/study/NCT04300244 NCT04300244] || Completed
| NIPU (UV1 Vaccine) || NCT04300244 || Completed
|}
|}


Line 456: Line 473:
== Related Resources ==
== Related Resources ==


* [[Asbestos Trust Funds]] — Access $30+ billion in asbestos trust fund compensation
* [[Trust Funds]] — Access $30+ billion in asbestos trust fund compensation
* [[Veterans Benefits]] — Veterans disability claims and healthcare coverage
* [[VA Benefits]] — Veterans disability claims and healthcare coverage
* [[Choosing a Mesothelioma Attorney]] — What to look for in mesothelioma legal representation
* [[Choosing an Attorney]] — What to look for in mesothelioma legal representation
* [[Mesothelioma Treatment Centers]] — Specialized mesothelioma treatment facilities nationwide
* [[Treatment Centers]] — Specialized mesothelioma treatment facilities nationwide
* [[Understanding Your Diagnosis]] — Medical information for newly diagnosed patients
* [[Understanding Your Diagnosis]] — Medical information for newly diagnosed patients


Revision as of 06:41, 24 February 2026

/Users/charlesfletcher/Library/Python/3.9/lib/python/site-packages/urllib3/__init__.py:35: NotOpenSSLWarning: urllib3 v2 only supports OpenSSL 1.1.1+, currently the 'ssl' module is compiled with 'LibreSSL 2.8.3'. See: https://github.com/urllib3/urllib3/issues/3020 

 warnings.warn(

Connecting to wikimesothelioma.com... Logging in as MesotheliomaSupport@Claude... Successfully logged in!

--- Page Content ---

🔬 Clinical Trials Quick Facts
January 2026 Trial Landscape
Active US Trials 53 Recruiting
Patient Participation Only 8%
CAR-T 1-Year Survival 83%
Best Response Rate 51.6% (BNT327)
Phase III Opening H1 2026 (VT3989)
New US Cases/Year ~3,000
🛡️ Free Case Review →

Mesothelioma Clinical Trials represent the cutting edge of treatment research, offering patients access to breakthrough therapies before they become widely available. As of January 2026, fifty-three mesothelioma clinical trials are actively recruiting patients across the United States, including revolutionary CAR-T cell therapies achieving 83% one-year survival, the first-ever Phase III trial of a TEAD inhibitor, and AI-designed drugs now in human testing.[1]

The mesothelioma clinical trial landscape has transformed dramatically, yet patient participation remains critically low at just 8% — a significant drop from 14% in 2023. This gap exists despite proven survival benefits from trial participation. In January 2026, patients have access to immunotherapy combinations extending median survival beyond 18 months, targeted therapies achieving 32% response rates in previously untreatable disease, and cellular therapies demonstrating unprecedented durability. The FDA approved pembrolizumab plus chemotherapy in September 2024 as a new first-line standard, with subcutaneous Keytruda QLEX following in January 2026. VT3989, the first TEAD inhibitor, will advance to Phase III registration trials in the first half of 2026, representing a major milestone for targeted therapy in this disease.

Mesothelioma clinical trials at a glance:

  • 53 actively recruiting trials — the number of mesothelioma clinical trials open to patients across the United States as of January 2026
  • 8% participation rate — patient enrollment has dropped from 14% in 2023 despite expanded trial options and proven survival benefits
  • 83% one-year survival — Memorial Sloan Kettering's intrapleural CAR-T program achieves dramatically higher survival than standard therapy
  • 32% response rate — VT3989 TEAD inhibitor advancing to Phase III in H1 2026 after demonstrating durable responses in relapsed patients
  • 51.6% overall response — BNT327/PM8002 bispecific antibody achieves exceptional results, with 75% response in peritoneal mesothelioma
  • 16.9 months median survival — pembrolizumab plus chemotherapy FDA approved September 2024 with 52% confirmed response rate
  • 23.2% three-year survival — CheckMate 743 nivolumab plus ipilimumab demonstrates sustained long-term benefit versus chemotherapy
  • First AI-designed drug — ISM6331 pan-TEAD inhibitor dosed its first patient January 22, 2025 after AI-accelerated development
  • Approximately 3,000 new cases — annual U.S. mesothelioma diagnoses with 72,779 total cases documented from 1999 to 2021
  • 90-day first payment — patients can pursue trust fund compensation simultaneously with clinical trial participation
Key Facts: Mesothelioma Clinical Trials January 2026
  • 53 actively recruiting mesothelioma clinical trials in the United States as of January 2026
  • 8% patient participation rate—down from 14% in 2023 despite expanded options
  • CAR-T cell therapy at Memorial Sloan Kettering achieves 83% one-year survival
  • VT3989 TEAD inhibitor advancing to Phase III in H1 2026 with 32% response rate
  • ISM6331—first AI-designed mesothelioma drug—dosed first patient January 22, 2025
  • Pembrolizumab + chemotherapy FDA approved September 2024; median survival 16.9 months
  • Keytruda QLEX (subcutaneous) approved January 11, 2026 for all indications
  • BNT327/PM8002 achieves 51.6% overall response rate; 75% in peritoneal mesothelioma
  • CheckMate 743 shows 23.2% three-year survival with nivolumab plus ipilimumab
  • Approximately 3,000 new US cases diagnosed annually; 72,779 total cases 1999-2021

What Phase III Trials Are Currently Recruiting?

Phase III trials represent the final stage before FDA approval and offer patients access to therapies that have already demonstrated efficacy in earlier studies.

eVOLVE-Meso Trial (NCT06097728)

The eVOLVE-Meso trial is a Phase III, randomized, open-label, multicenter study testing volrustomig (MEDI5752), a novel PD-1/CTLA-4 bispecific antibody, in combination with carboplatin and pemetrexed.[2]

Trial Specifications:

  • Status: Actively recruiting globally
  • Sponsor: AstraZeneca
  • Enrollment Target: 825 patients worldwide
  • Mechanism: PD-1/CTLA-4 bispecific antibody providing selective CTLA-4 blockade on activated T cells
  • Comparator Arms: Platinum-based chemotherapy or nivolumab plus ipilimumab
  • Eligibility: Unresectable pleural mesothelioma with no prior systemic therapy
  • Locations: United States, Canada, Brazil, China, Europe, Japan
  • Expected Completion: Data anticipated post-2026

ATOMIC-Meso Results (Pegargiminase/ADI-PEG20)

The ATOMIC-Meso trial has completed, with practice-changing results published in JAMA Oncology in March 2024.[3]

Published Results (249 patients with non-epithelioid pleural mesothelioma):

  • Median overall survival: 9.3 months versus 7.7 months with placebo plus chemotherapy
  • Three-year survival: Quadrupled compared to placebo arm
  • Progression-free survival: 6.2 months versus 5.6 months (HR 0.65; p=0.02)
  • Risk reduction: 35% reduction in progression risk
  • Mechanism: Arginine depletion therapy targeting ASS1-deficient tumors
"The ATOMIC-Meso results represent a breakthrough for patients with non-epithelioid mesothelioma, a subtype that historically had very limited treatment options. Quadrupling three-year survival changes the outlook for these patients and their families."
— Rod De Llano, Founding Partner, Danziger & De Llano

What CAR-T Cell Therapies Are Available for Mesothelioma?

CAR-T (Chimeric Antigen Receptor T-cell) therapy represents one of the most promising frontiers in mesothelioma treatment, with multiple trials demonstrating unprecedented survival outcomes.[4]

TNhYP218 Trial at National Cancer Institute (NCT06885697)

This Phase I dose-escalation study evaluates anti-mesothelin TNaive/SCM hYP218 CAR T cells, designed for enhanced tumor infiltration and persistence.

Trial Details:

  • Status: Recruiting since 2025
  • Location: National Cancer Institute, Bethesda, Maryland
  • Innovation: Targets membrane-proximal epitope of mesothelin, showing 2-4 fold better tumor killing than membrane-distal approaches in preclinical studies
  • Eligibility: Age 18 or older, mesothelin expression greater than 50% of tumor cells, ECOG 0-1
  • Monitoring: Patients must remain within 2 hours of NIH for 30 days post-infusion
  • Follow-up: 15 years per FDA requirement

Memorial Sloan Kettering Intrapleural CAR-T Program (NCT04577326)

This groundbreaking program pioneered regional delivery of CAR-T cells directly into the pleural space, minimizing systemic toxicity while maximizing tumor contact.[5]

Breakthrough Results: Memorial Sloan Kettering's intrapleural CAR-T program achieved 83% one-year survival for malignant pleural mesothelioma patients—dramatically exceeding historical outcomes of 12-16 months median survival with standard therapy.

Published Results:

  • One-year survival: 83% for malignant pleural mesothelioma patients
  • CAR-T persistence: Cells detected in peripheral blood for more than 100 days in 39% of patients
  • Durable responses: One patient achieved partial response lasting 26 months
  • Safety profile: Intrapleural administration was safe and well tolerated
  • Combination approach: 18 patients received CAR-T with pembrolizumab, demonstrating enhanced function

SynKIR-110 Trial (STAR-101, NCT05568680)

This novel approach uses KIR-CAR T cells targeting mesothelin across multiple tumor types including mesothelioma.[6]

  • Status: Completed enrollment of Cohorts 1-3 without dose-limiting toxicities as of May 2025
  • Sites: Multiple US locations including Penn Medicine
  • Safety: No dose-limiting toxicities in completed cohorts

What Targeted Therapies Are Showing Promise?

VT3989 TEAD Inhibitor — Advancing to Phase III

VT3989 represents a breakthrough in targeting the previously "undruggable" Hippo/YAP/TEAD pathway, which is dysregulated in the majority of mesotheliomas.[7]

ESMO 2025 Results (Published Nature Medicine December 2025):

  • Objective response rate: 32% in 22 mesothelioma patients at optimized dose
  • Disease control rate: 86% when incorporating optimal dose and UACR threshold
  • Median progression-free survival: 10 months
  • Duration of response: 8 patients on treatment more than 1 year; one approaching 2 years
  • Selected dose: 100 mg two-weeks-on/two-weeks-off for Phase III
  • Safety: Favorable profile with mostly grade 1-2 toxicities; proteinuria reversible with dose adjustment
  • Tumor types: Activity demonstrated in both NF2-mutant and wild-type tumors

Regulatory Designations:

  • FDA Orphan Drug Designation
  • FDA Fast Track Designation
Historic Milestone: VT3989 will become the first TEAD inhibitor to reach a registrational Phase III trial in mesothelioma when it opens in the first half of 2026, representing a major advance for targeted therapy in this disease.

ISM6331 — First AI-Designed Drug for Mesothelioma (NCT06566079)

This pan-TEAD inhibitor was designed using Insilico Medicine's Chemistry42 AI platform, representing the first AI-designed drug to enter clinical testing for mesothelioma.[8]

Development Timeline:

  • September 2020: AI platform launched
  • June 2023: Recommended for preclinical studies
  • April 2024: AACR presentation showing broad cancer-killing effects
  • June 2024: FDA Orphan Drug Designation granted
  • August 2024: IND clearance received
  • January 22, 2025: First patient dosed in China
  • 2026: US enrollment expected

Mechanism: Pan-TEAD inhibitor blocking the palmitoylation site, disrupting YAP/TAZ-TEAD transcriptional activity

IAG933 TEAD Inhibitor — Development Discontinued

Novartis discontinued development of IAG933 in October 2025 following underwhelming ESMO 2025 data showing only 13% objective response rate in 30 pleural mesothelioma patients. QTc prolongation dose-limiting toxicities in 4 patients contributed to the decision.[9]

What Are the Latest Immunotherapy Results?

Pembrolizumab Plus Chemotherapy — FDA Approved September 2024

The KEYNOTE-483 trial led to FDA approval for first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma on September 17, 2024.[10]

Trial Results:

  • Median overall survival: 16.9 months versus 14.1 months with chemotherapy alone
  • Hazard ratio: 0.79 (95% CI: 0.63-0.99; p=0.0209)
  • Confirmed objective response rate: 52% versus 29%
  • Median duration of response: 6.9 versus 6.8 months
  • Regimen: Pembrolizumab with pemetrexed and platinum chemotherapy

January 2026 Update: FDA approved Keytruda QLEX (subcutaneous pembrolizumab) on January 11, 2026, offering a 1-minute injection every 3 weeks as an alternative to IV infusion for all 38 pembrolizumab indications including mesothelioma.

Nivolumab Plus Ipilimumab — CheckMate 743 Long-term Data

CheckMate 743 remains the only Phase 3 trial demonstrating survival improvement sustained over 3 years with first-line immunotherapy in unresectable malignant pleural mesothelioma.[11]

Three-Year Follow-up Results:

  • Three-year overall survival: 23.2% versus 15.4% with chemotherapy
  • Sustained benefit: Observed regardless of histology
  • Duration of response: Longer with dual immunotherapy at 3 years
  • Safety: Consistent profile with no new signals at long-term follow-up
"Clinical trials represent the cutting edge of mesothelioma treatment. We encourage every patient to explore trial options because tomorrow's standard treatments are available today through these programs. The survival improvements we're seeing with newer therapies are remarkable."
— Paul Danziger, Founding Partner, Danziger & De Llano

BNT327/PM8002 — Exceptional Peritoneal Mesothelioma Results

This PD-L1/VEGF-A bispecific antibody demonstrated remarkable activity at ASCO 2025, particularly in peritoneal mesothelioma.[12]

Phase 2 Trial Results (31 patients with unresectable mesothelioma):

  • Confirmed overall response rate: 51.6%
  • Peritoneal mesothelioma cohort (8 patients): 75% ORR, 100% disease control rate
  • Median exposure: 16.0 months (95% CI 8.1-19.5)
  • Median follow-up: 19.3 months
  • Safety: 93.5% experienced grade 3/4 adverse events; no treatment-related deaths

Phase 3 trial planning is underway (NCT07133750 registered July 2025).

UV1 Vaccine Plus Checkpoint Inhibitors

The NIPU trial (Phase II, NCT04300244) demonstrated statistically significant survival improvement when UV1 telomerase vaccine was added to nivolumab plus ipilimumab.[13]

Results (118 patients randomized):

  • Median overall survival: 15.4 months with UV1 versus 11.1 months without—statistically significant
  • Median progression-free survival: 4.2 months versus 2.9 months
  • Objective response rate: 31% versus 16%
  • Safety: Comparable adverse event rates between groups
  • Regulatory Status: FDA Fast Track Designation granted February 2024

What Are the Eligibility Requirements for Most Trials?

Performance Status Requirements

Most mesothelioma clinical trials require patients to meet specific baseline criteria:[14]

ECOG Performance Status:

  • ECOG 0: Fully active, able to carry on all pre-disease activities without restriction
  • ECOG 1: Restricted in physically strenuous activity but ambulatory and able to carry out light work
  • ECOG 2: Some trials accept for exceptional cases
  • Alternative measure: Karnofsky score 70% or higher

Typical Laboratory Value Requirements

  • Absolute neutrophil count 1,500/μL or higher
  • Platelet count 100,000/μL or higher
  • Hemoglobin 9.0 g/dL or higher
  • Creatinine clearance 45 mL/min or higher
  • Bilirubin 1.5x upper limit of normal or lower

Disease Requirements

  • Histologically confirmed mesothelioma (pathology report required)
  • Measurable disease by modified RECIST criteria
  • No untreated brain metastases
  • Specific histology requirements vary by trial
  • Some trials require specific biomarker expression (mesothelin greater than 50% for certain CAR-T trials)
Important: Eligibility requirements vary significantly between trials. A patient who does not qualify for one trial may be eligible for others. Work with a mesothelioma specialist to identify all available options.

Where Are Major Clinical Trials Located?

National Cancer Institute (Bethesda, Maryland)

  • TNhYP218 CAR-T trial (NCT06885697)
  • Multiple additional mesothelioma studies
  • Travel assistance programs available[15]

MD Anderson Cancer Center (Houston, Texas)

  • 16+ active mesothelioma trials
  • VT3989 TEAD inhibitor trial (lead investigator: Dr. Timothy Yap)
  • Specialized mesothelioma program
  • Telemedicine consultations offered[16]

Memorial Sloan Kettering Cancer Center (New York)

  • Intrapleural CAR-T program (NCT04577326)
  • International patient services
  • Dedicated mesothelioma team

University of Chicago

  • ISM6331 trial site
  • ICARuS II peritoneal trial (NCT06057935)
  • Multiple systemic therapy trials

Princess Margaret Cancer Centre (Toronto)

  • SMARTER trial headquarters
  • International enrollment accepted
  • Modified surgical protocols

What Are the Financial Considerations for Trial Participation?

Costs Covered by Trial Sponsors

  • Study drug or intervention
  • Trial-specific tests and procedures
  • Additional monitoring visits required by protocol
  • Some travel expenses (varies by trial)

Patient/Insurance Responsibility

  • Standard of care treatments
  • Routine doctor visits
  • Hospital stays if not trial-related
  • Most travel and lodging expenses

Insurance Coverage

The Affordable Care Act requires most health plans to cover routine patient costs in clinical trials.[17]

  • Medicare: Covers qualifying trials for Medicare beneficiaries
  • Private insurance: 44 states require coverage; check your state's mandates
  • Medicaid: Coverage depends on state regulations
  • VA benefits: VA covers trial participation at approved facilities for eligible veterans
"Many families don't realize that pursuing legal compensation and participating in clinical trials can happen simultaneously. The two processes are completely separate, and pursuing one doesn't affect the other. We help families navigate both paths at once."
— Michelle Whitman, Attorney, Danziger & De Llano

What Survival Outcomes Can Patients Expect?

Current Survival Data by Treatment Type

Treatment Approach Median Overall Survival Notable Outcomes
Pembrolizumab + Chemotherapy 16.9 months FDA approved September 2024; 52% response rate
Nivolumab + Ipilimumab 18.1 months 23.2% three-year survival
MSK Intrapleural CAR-T Data maturing 83% one-year survival
VT3989 (Relapsed) Data maturing 10 months PFS; 32% response rate
CRS-HIPEC (Peritoneal) 53 months 47% five-year survival

[18]

What Trials Are Expected in 2026?

Confirmed Q1-Q2 2026 Trial Openings

VT3989 Phase III:

  • First registrational trial of a TEAD inhibitor in mesothelioma
  • Based on ESMO 2025 data showing 32% ORR
  • Third-line indication[19]

BNT327/PM8002 Phase III:

  • NCT07133750 registered July 2025
  • Building on exceptional Phase 2 results

ISM6331 US Enrollment:

  • Expected to open following January 2025 China enrollment
  • First AI-designed mesothelioma drug

MVdeltaC First-in-Human:

  • Measles virus-based immunotherapy
  • FDA Orphan Drug Designation June 2025
  • Clinical trial planned for 2026

Pipeline Developments

Antibody-Drug Conjugates (ADCs):

  • SGN-MesoC2 recruiting (updated November 2025)
  • Rinatabart Sesutecan (GEN1184/PRO1184) recruiting (updated December 2025)[20]

How Do I Find and Enroll in a Clinical Trial?

Primary Trial Resources

  • ClinicalTrials.gov: Official NIH database with all registered trials
  • NCI Cancer Information Service: 1-800-4-CANCER
  • EmergingMed Navigator: Free matching service
  • Lazarex Cancer Foundation: Financial assistance for trial costs[21]

Questions to Ask Before Enrolling

  1. What phase is the trial? (Phase I = safety focus, Phase II = efficacy, Phase III = comparison)
  2. What are the specific eligibility requirements?
  3. How many visits are required and where?
  4. What costs will I be responsible for?
  5. Can I leave the trial if needed?
  6. How will this affect my other treatment options?
  7. What are the known risks and potential benefits?
  8. What happens if the treatment works—can I continue receiving it?
"When my father was diagnosed with mesothelioma, we didn't know about clinical trials or the compensation available to us. Now I help families understand all their options—both medical and legal—so they can make informed decisions during an incredibly difficult time."
— David Foster, Client Advocate, Danziger & De Llano

Key NCT Numbers for Trial Verification

Trial Name NCT Number Status
eVOLVE-Meso (Volrustomig) NCT06097728 Recruiting
TNhYP218 CAR-T (NCI) NCT06885697 Recruiting
ISM6331 TEAD Inhibitor NCT06566079 Recruiting
MSK Intrapleural CAR-T NCT04577326 Recruiting
SynKIR-110 NCT05568680 Recruiting
ICARuS II (Peritoneal) NCT06057935 Recruiting
NERO (Niraparib) NCT05455424 Completed
NIPU (UV1 Vaccine) NCT04300244 Completed

[22]

Patients participating in clinical trials can simultaneously pursue legal compensation from asbestos trust funds and responsible companies. This compensation is entirely separate from trial participation and can help cover expenses not covered by the trial, including travel, lodging, lost wages, and care for family members.[23]

🛡️ Free Clinical Trial & Compensation Consultation

Our team helps families navigate both treatment options and legal rights.

Call (866) 222-9990 →

References

  1. ↑ Malignant Mesothelioma Lawyers, Danziger & De Llano
  2. ↑ Mesothelioma Compensation, Danziger & De Llano
  3. ↑ New Mesothelioma Treatments and Research, Mesothelioma.net
  4. ↑ Financial Compensation Form, Mesothelioma Lawyer Center
  5. ↑ New York Mesothelioma Lawyers, Danziger & De Llano
  6. ↑ Immunotherapy for Mesothelioma, Mesothelioma.net
  7. ↑ New Mesothelioma Treatments, MesotheliomaAttorney.com
  8. ↑ Mesothelioma Treatment Options, Mesothelioma Lawyer Center
  9. ↑ Mesothelioma Diagnosis, Mesothelioma Lawyer Center
  10. ↑ Mesothelioma Prognosis, Mesothelioma Lawyer Center
  11. ↑ Mesothelioma Treatment Options, Mesothelioma.net
  12. ↑ Peritoneal Mesothelioma, MesotheliomaAttorney.com
  13. ↑ Cancer Vaccine for Mesothelioma, Mesothelioma Lawyer Center
  14. ↑ Mesothelioma Diagnosis, Mesothelioma.net
  15. ↑ Maryland Mesothelioma Lawyers, Mesothelioma Lawyer Center
  16. ↑ Houston Mesothelioma Lawyer, Danziger & De Llano
  17. ↑ VA Mesothelioma Claims, Danziger & De Llano
  18. ↑ Multimodal Therapy for Mesothelioma, Mesothelioma.net
  19. ↑ Top Mesothelioma Treatment Centers, MesotheliomaAttorney.com
  20. ↑ Latest Mesothelioma Research, Mesothelioma.net
  21. ↑ Clinical Trials for Mesothelioma, Mesothelioma.net
  22. ↑ Mesothelioma Lawyers, Mesothelioma Lawyer Center
  23. ↑ Mesothelioma Settlements, Danziger & De Llano
Retrieved from "https://wikimesothelioma.com/w/index.php?title=Clinical_Trials&oldid=1573"